Ken DeSantes, MD, has received an award of $136,000 from the Solving Kid’s Cancer Foundation to develop and pursue a collaborative research study titled “Phase I Trial of Ex-Vivo Expanded Haploidentical NK Cells and Hu14.18-IL2 for Children with Relapsed/Refractory Neuroblastoma”.
This proposed trial presents an innovative clinical approach towards cellular immunotherapy that is directed by antibody recognition.